Mental or Behavioral Dysfunction – Page 7

Seaport Therapeutics Secures $225M Series B Funding to Revolutionize Neuropsychiatric Medicines

11 months ago talkbio0Tagged clinical-stage pipeline, Depressive disorder, Glyph technology platform, neuropsychiatric medicines, Seaport, Series B

Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, clinical-stage pipeline, major depressive disorder, generalized anxiety disorder.

Supernus’ SPN-820 Shows Rapid Symptom Improvement in Major Depressive Disorder

11 months ago talkbio0Tagged Clinical Trials, Major Depressive Disorder, MDD, Mental Depression, Rapid-Acting, SPN-820, Supernus Pharmaceuticals, Unipolar Depression

Supernus Pharmaceuticals, SPN-820, Major Depressive Disorder (MDD), Rapid-Acting Depression Treatment, Clinical Trial Results

Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy

12 months ago talkbio0Tagged Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, New, psychiatric medication, Schizophrenia, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication

BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis

12 months ago talkbio0Tagged Alzheimer's Disease, Approved, KarXT, Mechanism (attribute), Muscarinic Agonists, Myers, Psychotic Disorders, Schizophrenia, squibb, United States Food and Drug Administration

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.